Synthesis and characterisation of [(η6-cymene)Ru(L)X2] compounds: single crystal X-ray structure of [(η6-cymene)Ru(P{OPh}3)Cl2] at 203 K

Experimental insights into catalytic oxidation of 1,6-hexanediol to ε-caprolactone over (p-cymene)RuCl2(L) complexes in non-polar media

The activity-pocket site dimension (θc) dependence of (p-cymene)RuCl2(L) supports associative interchange mechanism for 1,6-hexandiol oxidation to ε-caprolactone. Methyl isobutyl carbinol, a H-accepting product, reacts with Ru, causing deactivation.

Heterobimetallic Coinage Metal-Ruthenium Complexes Supported by Anionic N-Heterocyclic Carbenes

The lithium complexes [(WCA‐NHC)Li(toluene)] of anionic N‐heterocyclic carbenes with a weakly coordinating borate moiety (WCA‐NHC, WCA=B(C₆F₅)₃, NHC=IDipp=1,3‐bis(2,6‐diisopropylphenyl)imidazolin‐2‐ylidene) were used for the preparation of silver(I) or copper(I) WCA‐NHC complexes. While the reactions in THF with AgCl or CuCl afforded anionic mono‐ and dicarbene complexes with solvated lithium counterions [Li(THF)_n]⁺ (n=3, 4), the reactions in toluene proceeded with elimination of LiCl and formation of the neutral phosphine and arene complexes [(WCA‐NHC)M(PPh₃)] and [(WCA‐NHC)M(η²‐toluene)] (M=Ag, Cu). The latter were used for the preparation of chlorido‐ and iodido‐bridged heterobimetallic Ag/Ru and Cu/Ru complexes [(WCA‐NHC)M(μ‐X)₂Ru(PPh₃)(η⁶‐p‐cymene)] (M=Ag, Cu, X=Cl; M=Ag, X=I). Surprisingly, these complexes resisted the elimination of CuCl, AgCl, or AgI, precluding WCA‐NHC transmetalation.

Piano-Stool Ruthenium(II) Complexes with Delayed Cytotoxic Activity: Origin of the Lag Time

We have recently reported a series of piano-stool ruthenium(II) complexes of the general formula [RuCl₂(η⁶-arene)(P(1-pyrenyl)R²R³)] showing excellent cytotoxic activities (particularly when R² = R³ = methyl). In the present study, new members of this family of compounds have been prepared with the objective to investigate the effect of the steric hindrance of a bulky phosphane ligand, namely diisopropyl(1-pyrenyl)phosphane (L), on exchange reactions involving the coordinated halides (X = Cl, I). Two η⁶-arene rings were used, i.e. η⁶-methyl benzoate (mba) and η⁶-p-cymene (p-cym), and four complexes were synthesized, namely [RuCl₂(mba)(L)] (1_Cl2^iPr), [RuI₂(mba)(L)] (1_I2^iPr), [RuCl₂(p-cym)(L)] (2_Cl2^iPr), and [RuI₂(p-cym)(L)] (2_I2^iPr). Unexpectedly, all of the complexes exhibited poor cytotoxic activities after 24 h of incubation with cells, in contrast to the related compounds previously reported. However, it was observed that aged DMSO solutions of 2_I2^iPr (from 2 to 7 days) exhibited better activities in comparison to freshly prepared solutions and that the activity improved over “aging” time. Thorough studies were therefore performed to uncover the origin of this lag time in the cytotoxicity efficiency. The data achieved clearly demonstrated that compounds 2_I2^iPr and 2_Cl2^iPr were undergoing a series of transformation reactions in DMSO (with higher rates for the iodido complex 2_I2^iPr), ultimately generating cyclometalated species through a mechanism involving DMSO as a coordinated proton abstractor. The cyclometalated complexes detected in solution were subsequently prepared; hence, pure [RuCl(p-cym)(κ²C-diisopropyl(1-pyrenyl)phosphane)] (3_Cl^iPr), [RuI(p-cym)(κ²C-diisopropyl(1-pyrenyl)phosphane)] (3_I^iPr), and [Ru(p-cym)(κS-dmso)(κ²C-diisopropyl(1-pyrenyl)phosphane)]PF₆ (3_dmso^iPr) were synthesized and fully characterized. Remarkably, 3_Cl^iPr, 3_I^iPr, and 3_dmso^iPr are all very efficient cytotoxic agents, exhibiting slightly better activities in comparison to the chlorido noncyclometalated complexes [RuCl₂(η⁶-arene)(P(1-pyrenyl)R²R³)] described in an earlier report. For comparison purposes, the iodido compounds [RuI₂(mba)(dimethyl(1-pyrenyl)phosphane)] (1_I2^Me) and [RuI₂(p-cym)(dimethyl(1-pyrenyl)phosphane)] (2_I2^Me), bearing the less hindered dimethyl(1-pyrenyl)phosphane ligand, have also been prepared. The cytotoxic and chemical behaviors of 1_I2^Me and 1_I2^Me were comparable to those of their chlorido counterparts reported previously.

DMSO gradually converts half-sandwich, 1-pyrenyl-containing ruthenium(II) complexes into cyclometalated species showing notable cytotoxic properties.

Electronic effects in mixed N-heterocyclic carbene/phosphite indenylidene ruthenium metathesis catalysts

Five new complexes [RuCl₂(SIMes)(Ind)(O-pXC₅H₄)] bearing different para-substituted triphenylphosphites (X = H, OCH₃, CF₃, Cl, SF₅ and CN) were synthesised and used to study the effect of the electronic properties of the phosphite on olefin metathesis activity. Investigations of the physical properties of the new ligands and complexes were performed using physicochemical and DFT calculations. The catalytic activity of the complexes was benchmarked in challenging ring closing metathesis transformations featuring the formation of tetra-substituted double bonds. Complex [RuCl₂(SIMes)(Ind)P(O-pCF₃C₅H₄)₃] (3c) exhibited a particularly high catalytic activity, superior to state-of-the-art catalysts, and was further tested on a wide range of substrates.

Antiparasitic activity and ultrastructural alterations provoked by organoruthenium complexes against Leishmania amazonensis

New organoruthenium complexes were synthetized, characterized and evaluated to inhibit the proliferation of the Leishmania amazonensis parasite.

Anti-Proliferative and Anti-Migration Activity of Arene–Ruthenium(II) Complexes with Azole Therapeutic Agents

The efficacy of organoruthenium complexes containing ergosterol biosynthesis inhibitors (CTZ: clotrimazole, KTZ: ketoconazole and FCZ: fluconazole) against tumor cells, and their interaction with important macro-biomolecules such as human serum albumin and DNA have been investigated here. Our experimental results indicated that these ruthenium(II) complexes present spontaneous electrostatic interactions with albumin, and act as minor groove binders with the DNA. The ability of these Ru(II)–azole complexes to inhibit the proliferation of selected human tumor and non-tumor cell lines was determined by MTT assay. Complexes [RuCl(CTZ)(η6-p-cymene)(PPh3)]PF6 (3) and [RuCl(KTZ)(η6-p-cymene)(PPh3)]PF6 (4) were shown to be between 3- and 40-fold more cytotoxic than the free ligands and the positive control cisplatin. Complex 3 was selected to continue studies on the triple negative breast tumor cell line MDA-MB-231, inducing morphological changes, loss of adhesion, inhibition of colony formation, and migration through Boyden chambers, cell cycle arrest in the sub-G1 phase, and a mechanism of cell death by apoptosis. All these interesting results show the potential of this class of organometallic Ru(II) complexes as an antiproliferative agent.

Azobenzene-based ruthenium(ii) catalysts for light-controlled hydrogen generation

Photo-controlled hydrogen generation catalysts were developed based on ruthenium(ii) azobenzene-containing half-sandwich complexes.

Zinc oxide nanocrystal quenching of emission from electron-rich ruthenium-bipyridine complexes

A series of heteroleptic bipyridine ruthenium complexes were prepared using known synthetic methods. Each compound incorporated one electron withdrawing 4,4'-dicarboxylic acid-2,2'-bipyridine and two bipyridines each of which had electron donating dialkylamine substituents in the 4 and 4' positions. The electronic absorption spectra exhibited absorptions that moved to lower energy as the donor ability of the amine substituent increased. Density functional calculations established that the HOMO was delocalized over the metal and two pyridine groups located trans to the pyridines of the dicarboxylic acid bipyridine. The LUMO was delocalized over the dicarboxylic acid bipyridine. Cyclic voltammetry of the deprotonated compounds exhibit one quasi-reversible oxidation and three reductions. Coupled with the emission data, the excited state reduction potentials were estimated to range from -0.93 to -1.03 V vs. NHE. Monodispersed 3.2 nm diameter nanocrystals (NCs) of zinc oxide were found to quench partially the excited state of the dyes via a static quenching electron transfer process involving the formation of a dyad of the complex and the NC. The magnitude of the partial quenching of complexed dyes was correlated to the distribution of band gaps for the NCs, which is an inverse function of diameter. Dyes attached to the NCs on the small end of the particle size distribution had electron transfer rates that were uncompetitive with radiative and nonradiative decay mechanisms.

Somatostatin subtype-2 receptor-targeted metal-based anticancer complexes

Conjugates of a dicarba analogue of octreotide, a potent somatostatin agonist whose receptors are overexpressed on tumor cells, with [PtCl(2)(dap)] (dap = 1-(carboxylic acid)-1,2-diaminoethane) (3), [(η(6)-bip)Os(4-CO(2)-pico)Cl] (bip = biphenyl, pico = picolinate) (4), [(η(6)-p-cym)RuCl(dap)](+) (p-cym = p-cymene) (5), and [(η(6)-p-cym)RuCl(imidazole-CO(2)H)(PPh(3))](+) (6), were synthesized by using a solid-phase approach. Conjugates 3-5 readily underwent hydrolysis and DNA binding, whereas conjugate 6 was inert to ligand substitution. NMR spectroscopy and molecular dynamics calculations showed that conjugate formation does not perturb the overall peptide structure. Only 6 exhibited antiproliferative activity in human tumor cells (IC(50) = 63 ± 2 μM in MCF-7 cells and IC(50) = 26 ± 3 μM in DU-145 cells) with active participation of somatostatin receptors in cellular uptake. Similar cytotoxic activity was found in a normal cell line (IC(50) = 45 ± 2.6 μM in CHO cells), which can be attributed to a similar level of expression of somatostatin subtype-2 receptor. These studies provide new insights into the effect of receptor-binding peptide conjugation on the activity of metal-based anticancer drugs, and demonstrate the potential of such hybrid compounds to target tumor cells specifically.

A new promising application for highly cytotoxic metal compounds: η6-areneruthenium(II) phosphite complexes for the treatment of alveolar echinococcosis

Two series of η(6)-areneruthenium(II) phosphite complexes were prepared, characterized, and evaluated in vitro for their toxic potential against Echinococcus multilocularis metacestodes. Neutral complexes of general formula [(η(6)-p-cymene)RuCl(2){P(OR)(3)}] (R = Et, (i)Pr, Ph) with two easily exchangable chloride ligands showed only minor toxicity, whereas the substitution of these moieties against a β-diketonate (2,2,6,6-tetramethylheptanedionate) ligand led to hydrolytically stable complex salts of type [(η(6)-p-cymene)Ru(β-diketonate){P(OR)(3)}][BF(4)] (R = Et, (i)Pr, Ph) with comparable in vitro toxicity (50% PGI release at c = 1.4 - 4.7 μM) to the reference drug nitazoxanide (50% PGI release at c = 1.2 μM). In addition, the latter complexes were highly toxic against rat hepatoma cells (IC(50) = 0.40-2.0 μM) and less toxic against human foreskin fibroblasts (IC(50) = 1.1-2.9 μM) and Vero cells (IC(50) = 1.2-8.9 μM). The measured cytotoxicities against mammalian cells are, to the best of our knowledge, among the highest ever observed for ruthenium-based complexes. In conclusion, complex salts of type [(η(6)-p-cymene)Ru(β-diketonate){P(OR)(3)}][BF(4)] might be interesting candidates for further development toward anthelmintic drugs and/or highly cytotoxic metal compounds.

A SAR study of novel antiproliferative ruthenium and osmium complexes with quinoxalinone ligands in human cancer cell lines

A series of ruthenium(II) arene complexes with 3-(1H-benzimidazol-2-yl)-1H-quinoxalin-2-one, bearing pharmacophoric groups of known protein kinase inhibitors, and related benzoxazole and benzothiazole derivatives have been synthesized. In addition, the corresponding osmium complexes of the unsubstituted ligands have also been prepared. The compounds have been characterized by NMR, UV-vis, and IR spectroscopy, ESI mass spectrometry, elemental analysis, and by X-ray crystallography. Antiproliferative activity in three human cancer cell lines (A549, CH1, SW480) was determined by MTT assays, yielding IC(50) values of 6-60 μM for three unsubstituted metal-free ligands, whereas values for the metal complexes vary in a broad range from 0.3 to 140 μM. Complexation with osmium of quinoxalinone derivatives with benzimidazole or benzothiazole results in a more consistent increase in cytotoxicity than complexation with ruthenium. For selected compounds, the capacity to induce apoptosis was confirmed by fluorescence microscopy and flow-cytometric analysis, whereas cell cycle effects are only moderate.